These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 17652107)

  • 1. Assessment of cancer immunotherapy outcome in terms of the immune response time features.
    Rodríguez-Pérez D; Sotolongo-Grau O; Espinosa Riquelme R; Sotolongo-Costa O; Santos Miranda JA; Antoranz JC
    Math Med Biol; 2007 Sep; 24(3):287-300. PubMed ID: 17652107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune system-tumour efficiency ratio as a new oncological index for radiotherapy treatment optimization.
    Sotolongo-Grau O; Rodríguez-Pérez D; Santos-Miranda JA; Sotolongo-Costa O; Antoranz JC
    Math Med Biol; 2009 Dec; 26(4):297-307. PubMed ID: 19584118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A cellular automaton model of cancerous growth.
    Qi AS; Zheng X; Du CY; An BS
    J Theor Biol; 1993 Mar; 161(1):1-12. PubMed ID: 8501923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Immune response and cancer].
    El Hage F; Abouzahr-Rifai S; Meslin F; Mami-Chouaib F; Chouaib S
    Bull Cancer; 2008 Jan; 95(1):57-67. PubMed ID: 18230571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mathematical model of pulsed immunotherapy for superficial bladder cancer.
    Bunimovich-Mendrazitsky S; Byrne H; Stone L
    Bull Math Biol; 2008 Oct; 70(7):2055-76. PubMed ID: 18716846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours.
    Conroy H; Marshall NA; Mills KH
    Oncogene; 2008 Jan; 27(2):168-80. PubMed ID: 18176598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Virus-based immunotherapy of cancer: what do we know and where are we going?
    Sørensen MR; Thomsen AR
    APMIS; 2007 Nov; 115(11):1177-93. PubMed ID: 18092950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The immune system--is it relevant to cancer development, progression and treatment?
    Prestwich RJ; Errington F; Hatfield P; Merrick AE; Ilett EJ; Selby PJ; Melcher AA
    Clin Oncol (R Coll Radiol); 2008 Mar; 20(2):101-12. PubMed ID: 18037277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Immunotherapy in radical surgery of colorectal carcinoma].
    Brivio F; Fumagalli L; Chiarelli M; Denova M; Bertolini A; Cetta M; Nespoli A
    Chir Ital; 2007; 59(5):635-40. PubMed ID: 18019635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A model of immune regulation as a consequence of randomized lymphocyte division and death times.
    Hawkins ED; Turner ML; Dowling MR; van Gend C; Hodgkin PD
    Proc Natl Acad Sci U S A; 2007 Mar; 104(12):5032-7. PubMed ID: 17360353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity.
    Ménard C; Martin F; Apetoh L; Bouyer F; Ghiringhelli F
    Cancer Immunol Immunother; 2008 Nov; 57(11):1579-87. PubMed ID: 18369619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumour suppression by immune system through stochastic oscillations.
    Caravagna G; d'Onofrio A; Milazzo P; Barbuti R
    J Theor Biol; 2010 Aug; 265(3):336-45. PubMed ID: 20580640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
    Khawli LA; Hu P; Epstein AL
    Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determination of the optimal therapeutic protocols in cancer immunotherapy.
    Cappuccio A; Castiglione F; Piccoli B
    Math Biosci; 2007 Sep; 209(1):1-13. PubMed ID: 17416392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Tumours and immunity. II. Special part. Tumour antigens. The immune response by neoplasms. Immunotherapy].
    Ulvund MJ
    Nord Vet Med; 1972; 24(7):380-7. PubMed ID: 4666480
    [No Abstract]   [Full Text] [Related]  

  • 16. Cancer immunotherapy.
    Baxevanis CN; Perez SA; Papamichail M
    Crit Rev Clin Lab Sci; 2009; 46(4):167-89. PubMed ID: 19650714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Making and circumventing tolerance to cancer.
    Kammertoens T; Blankenstein T
    Eur J Immunol; 2009 Sep; 39(9):2345-53. PubMed ID: 19634191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of the conventional antitumor therapies surgery, chemotherapy, radiotherapy and immunotherapy on regulatory T lymphocytes in cancer patients.
    Lissoni P; Brivio F; Fumagalli L; Messina G; Meregalli S; Porro G; Rovelli F; Vigorè L; Tisi E; D'Amico G
    Anticancer Res; 2009 May; 29(5):1847-52. PubMed ID: 19443415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Developmental immunotoxicology (DIT): windows of vulnerability, immune dysfunction and safety assessment.
    Dietert RR
    J Immunotoxicol; 2008 Oct; 5(4):401-12. PubMed ID: 19404874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Scientific rationale for the Finnish Allergy Programme 2008-2018: emphasis on prevention and endorsing tolerance.
    von Hertzen LC; Savolainen J; Hannuksela M; Klaukka T; Lauerma A; Mäkelä MJ; Pekkanen J; Pietinalho A; Vaarala O; Valovirta E; Vartiainen E; Haahtela T
    Allergy; 2009 May; 64(5):678-701. PubMed ID: 19383025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.